Center Trials & Treatment
6
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
50.0%
3 terminated/withdrawn out of 6 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma
Role: collaborator
A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus
Role: lead
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Role: lead
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Role: lead
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Role: lead
Expanded Access for Pembrolizumab (MK-3475)
Role: lead
All 6 trials loaded